ArticleBMC cancer2025
Can the detection of serum glutathione reductase serve as an effective complement to traditional tumor biomarkers in clinical laboratory medicine for patients with hepatocellular carcinoma?
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the most prevalent malignancies within the digestive system, characterized by alarmingly high incidence and mortality rates. Early screening and diagnosis play a crucial role in the treatment and prognosis of HCC patients. We investigated whether the detection of serum glutathione reductase (GR) can serve as an effective complement to traditional tumor biomarkers in clinical laboratory medicine for patients with HCC.
methodsWe analyzed the positive rates and levels of serum GR, alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-Ⅱ (PIVKA-Ⅱ), carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) in 330 patients with HCC, 160 patients with benign liver tumors (BLT), 260 patients with chronic hepatitis B (CHB), 220 patients with liver cirrhosis (LC), and 280 healthy controls (HCs). The diagnostic performance of five biomarkers and their combinations for HCC patients and AFP-negative HCC patients was evaluated using receiver operating characteristic (ROC) curves and area under the curve (AUC) analysis. Additionally, we investigated the correlation between the levels of GR, PIVKA-Ⅱ or AFP and the clinicopathological parameters of patients with HCC.
resultsThe positive rates and levels of GR, AFP, PIVKA-II, CEA, and CA19-9 were significantly higher in the HCC group, the early HCC group, and the advanced HCC group than in the control group (p < 0.001). In the advanced HCC group, the positivity rates and levels of GR, AFP, and PIVKA-Ⅱ were markedly higher than those in the early HCC group (p < 0.01). PIVKA-Ⅱ exhibited the highest AUC and sensitivity for HCC diagnosis, at 0.873 (95% CI 0.853-0.891) and 72.7%, respectively, with a specificity of 94.9%. GR demonstrated exceptional diagnostic capability for patients with AFP-negative HCC, AFP-negative early HCC, and AFP-negative advanced HCC, with AUC values ranging from 0.864 to 0.881, sensitivity between 46.4% and 71.4%, and specificity of 97.7% (p < 0.001). Among all possible combinations, the combined detection of the five biomarkers yielded the highest AUC and sensitivity for diagnosing HCC, at 0.922 (95% CI 0.906-0.936) and 90.3%, respectively. The levels of GR, AFP, and PIVKA-Ⅱ exhibited varying degrees of correlation with the clinicopathological parameters of HCC patients.
conclusionsThe detection of serum GR can serve as an effective complement to traditional tumor biomarkers in clinical laboratory medicine for HCC patients, particularly those with AFP-negative HCC. The combined detection of GR, AFP, PIVKA-Ⅱ, CEA, and CA19-9 can significantly enhance the diagnostic performance of HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.